CMOH-01 is under clinical development by Curatis and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CMOH-01’s likelihood of approval (LoA) and phase transition for Neuropathic Pain (Neuralgia) took place on 19 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CMOH-01 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CMOH-01 overview

C-MOH-01 is under development for the treatment of medication overuse headache. It is a repurposed drug candidate. The drug candidate was also under development for the treatment of tension-type headache.

Curatis overview

Curatis is a healthcare services provider. Established in 2002, it is headquartered in Switzerland.

Quick View CMOH-01 LOA Data

Report Segments
  • Innovator
Drug Name
  • CMOH-01
Administration Pathway
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.